JP2004511492A - ビクニンを含む血漿画分、その調製方法、およびその使用 - Google Patents

ビクニンを含む血漿画分、その調製方法、およびその使用 Download PDF

Info

Publication number
JP2004511492A
JP2004511492A JP2002534368A JP2002534368A JP2004511492A JP 2004511492 A JP2004511492 A JP 2004511492A JP 2002534368 A JP2002534368 A JP 2002534368A JP 2002534368 A JP2002534368 A JP 2002534368A JP 2004511492 A JP2004511492 A JP 2004511492A
Authority
JP
Japan
Prior art keywords
bikunin
plasma fraction
plasma
chromatography
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002534368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511492A5 (https=
Inventor
ヨージック　デューロ
Original Assignee
オクタファルマ　アクチェン　ゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オクタファルマ　アクチェン　ゲゼルシャフト filed Critical オクタファルマ　アクチェン　ゲゼルシャフト
Publication of JP2004511492A publication Critical patent/JP2004511492A/ja
Publication of JP2004511492A5 publication Critical patent/JP2004511492A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2002534368A 2000-10-13 2001-10-11 ビクニンを含む血漿画分、その調製方法、およびその使用 Pending JP2004511492A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10050665 2000-10-13
PCT/EP2001/011994 WO2002030983A2 (de) 2000-10-13 2001-10-11 Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung

Publications (2)

Publication Number Publication Date
JP2004511492A true JP2004511492A (ja) 2004-04-15
JP2004511492A5 JP2004511492A5 (https=) 2005-03-17

Family

ID=7659599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002534368A Pending JP2004511492A (ja) 2000-10-13 2001-10-11 ビクニンを含む血漿画分、その調製方法、およびその使用

Country Status (5)

Country Link
US (1) US20030190732A1 (https=)
EP (1) EP1326893A2 (https=)
JP (1) JP2004511492A (https=)
AU (1) AU2002216968A1 (https=)
WO (1) WO2002030983A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518368A (ja) * 2005-12-07 2009-05-07 ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ ソシエテ アノニム 因子ｈ濃縮物の調製方法及び薬剤の形でのその使用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536206A (ja) * 2003-10-16 2007-12-13 バイエル・ヘルスケア・エルエルシー 尿中トリプシンインヒビターを検出するためのモノクローナル抗体
EP3087991A1 (en) * 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN103142650B (zh) * 2004-11-05 2016-05-11 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CN106928346B (zh) * 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
SG187599A1 (en) 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846763A (en) * 1991-01-14 1998-12-08 New York University DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6)
FR2711371B1 (fr) * 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518368A (ja) * 2005-12-07 2009-05-07 ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ ソシエテ アノニム 因子ｈ濃縮物の調製方法及び薬剤の形でのその使用

Also Published As

Publication number Publication date
AU2002216968A1 (en) 2002-04-22
WO2002030983A3 (de) 2002-12-12
EP1326893A2 (de) 2003-07-16
WO2002030983A2 (de) 2002-04-18
US20030190732A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
RU1837880C (ru) Способ разделени белков крови
US6069236A (en) Immunoglobulin G concentrate for therapeutic use and process for producing said concentrate
CA2192683C (en) Filtration
RU2266914C2 (ru) Способ получения igg
US5164487A (en) Manufacturing intravenous tolerable immunoglobulin-g preparation
RU2603103C2 (ru) Способ получения фибриногена с использованием сильной анионообменной смолы и содержащий фибриноген продукт
US6921808B2 (en) Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc-globulin and a Gc-globulin medicinal product
US6465624B1 (en) Purification of von-Willebrand factor by cation exchanger chromatography
JP2004511492A (ja) ビクニンを含む血漿画分、その調製方法、およびその使用
EP1519944B1 (en) Processes for the preparation of fibrinogen
US9663553B2 (en) Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
CA2006684C (en) Monoclonal antibody against protein c
MX2011000666A (es) Metodo para preparar inhibidor de alfa-1 proteinasa.
US5252217A (en) Blood coagulation factor XI concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
RU2627162C2 (ru) Получение иммуноглобулинов с пониженным содержанием тромбогенных агентов и иммуноглобулиновая композиция
RU2649363C2 (ru) СПОСОБЫ СНИЖЕНИЯ И/ИЛИ УДАЛЕНИЯ FXI и FXIa ИЗ РАСТВОРОВ, СОДЕРЖАЩИХ УКАЗАННЫЕ ФАКТОРЫ СВЕРТЫВАНИЯ
US5777081A (en) Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained
JP2001524953A (ja) 免疫寛容プロトロンビン複合体の調製
JPS58201794A (ja) ヒトインターフェロンβの濃縮精製法
JP3471379B2 (ja) ヒトアンチトロンビン−ｉｉｉの調製方法
JPH07330626A (ja) 血清アルブミン製剤の製造方法
AU2005203243A1 (en) Process for the preparation of a Von Willebrad (FvW) factor concentrate by chromatography and a FvW concentrate thus obtainable
JPH08225599A (ja) Ｃ１−エステラーゼ阻害剤濃厚物（ｃ１−ｉｎｈ）の調製法、および治療的使用のための得られた濃厚物
CN116322920A (zh) 使用氧化硅吸附从血浆中纯化fviii
JPH05170799A (ja) ヒトインターロイキン８の精製方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070626